Her-2/Neu Oncogene Amplification and Protein Over-expression in Interval and Screen-detected Breast Cancers

Anticancer Research

Volumn 23, Issue 5 B, 2003, Pages 4213-4218

  Anttinen, Jorma ^a   Kuopio, Teijo ^a   Nykanen, Marjukka ^a   Torkkeli, Helena ^b   Saari, Urpo ^c   Juhola, Matti ^a  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c Cancer Society of Finland   (Finland)

Author keywords

Breast cancer; Cancer screening; Her 2 neu; In situ hybridization; Interval cancer; Mammography

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER SCREENING; CHROMOSOME; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE; GENE OVEREXPRESSION; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; LYMPH NODE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 0344872722     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Andrulis IL, Bull SB, Blackstein ME et al: Neu/erbB2 amplification identifies a poor-prognosis group of women with node-negative breast carcinoma. Toronto breast cancer study group. J Clin Oncol 16: 1340-9, 1998.
2. Brekelmans CT, Peeters PH, Deurenberg JJ and Collette HJ: Survival in the DOM screening programme. Eur J Cancer 31A: 1830-35, 1995.
3. Burhenne HJ, Burhenne KW, Goldberg F et al: Interval breast carcinomas in the screening mammography program of British Columbia: Analysis and classification. Am J Roentgenology 162: 1067-71, 1994.
4. Burrel HC, Sibbering DM, Wilson ARM et al: Screening interval breast cancer: mammographic features and prognostic factors. Radiology 199: 811-17, 1996.
5. Clark G: Should selection of adjuvant chemotherapy for patients with breast cancer be based on erb-2 status? J Natl Cancer Inst 90: 1320-21, 1998.
6. Cowan WK, Kelly P, Sawan A et al: The pathological and biological nature of screen detected breast carcinomas: a morphological and immunohistochemical study. J Pathol 182: 29-35, 1997
7. Cowan WK, Angus B, Gray JC, Lunt LG and Al-Tamini SR: A study of interval cancers within the NHS breast screening programme. J Clin Pathol 53: 140-6, 2000.
8. Crosier M, Scott D, Wilson RG, Griffith CDM, May FEB and Wesley BE: Differences in Ki67 and c-erbB2 expression between screen detected and true interval breast cancers. Clin Cancer Res 5: 2682-88, 1999.
9. DeGroote R, Rush BF, Milazzo J, Warden MJ and Rock JM: Interval breast carcinoma more aggressive subset of breast neoplasia. Surgery 94: 543-47, 1983.
10. Everington D, Gilbert FJ, Tyack C et al: The Scottish breast screening programme's experience of monitoring interval cancer. J Med Screen 6: 21-27, 1999.
11. Faux AM, Richardson DC, Lawrence DM et al: Interval breast cancers in the NHS breast screening programme: does the current definition exclude too many? J Med Screen 4: 169-172, 1997.
12. Frisel J, Eklund G, Helström L and Somell A: Analysis of interval carcinomas in a randomised screening trial in Stockholm. Breast Cancer Res Treat 9: 219-225, 1987.
13. Gancberg D, Lespagnard L, Rous G et al: Sensitivity of Her-2/neu antibodies in archival tissue samples of invasive breast carcinoma. Am J Clin Pathol 113: 675-82, 2000.
14. Gilliland FD, Joste N, Stauber PM et al: Biologic characteristics of interval and screen-detected breast carcinomas. J Natl Cancer Inst 92: 743-49, 2000.
15. Hanna W, Kahn HJ and Trudeau M: Evaluation of Her-2/neu(erbB-2) status in breast carcinoma from bench to bedside. Mod Pathol 12: 827-34, 1999.
16. Hoang MP, Aysegul AS, Ordonez NG and Sneige N: Her-2/neu gene amplification compared with Her-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113: 852-59, 2000.
17. Ikeda DM, Andersson I, Watsgard C, Janzon L and Linel F: Interval carcinomas in the Malmö mammographic screening trial: radiographic appearance and prognostic considerations Am J Roentgenology 159: 287-94, 1992.
18. Jimenez RE, Wallis T, Tabascza P and Visscher DW: Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridisation. Mod Pathol 13: 37-45, 2000.
19. Klemi PJ, Toikkanen S, Räsänen O, Parvinen I and Joensuu H: Mammography screening interval and the frequency of interval carcinomas in a population-based screening. Br J Cancer 75: 762-66, 1997.
20. Moberg K, Grundstom H, Tornberg S et al: Two models for radiological reviewing of interval cancers. J Med Screen 6: 35-9, 1999.
21. Peeters PMH, Verbeek AML, Hendriks JHCL et al: The predictive value of positive test results in screening for breast cancer by mammography in Nijmegen programme. Br J Cancer 56: 667-671, 1987.
22. Porter PL, El-Bastawissi EY, Mandelson MT et al: Breast tumour characteristics as predictor of mammographic detection: comparison of interval- and screen detected cancers. J Natl Cancer Inst 91: 2020-28, 1999.
23. Ridolfi RL, Jamehdor MR and Arber JR: Her-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridisation approach. Mod Pathol 13: 866-73, 2000.
24. Ross JS and Fletcher JA: Her-2 neu (c-erb-B2) gene and protein in breast carcinoma. Am J Clin Pathol 112: S53-S67, 1999.
25. Sjögren S, Inganas M, Lindgren A, Holmberg L and Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast carcinoma, alone and in combination with other prognostic markers. J Clin Oncol 16: 462-93, 1998.
26. Sylvester PA, Vipond MN and Kutt E: Rate and classification of interval cancers in the breast screening programme. Ann R Coll Surg 79: 276-277, 1997.
27. Tanner M, Gancberg D, DiLeo A et al: Chromogen in situ hybridisation. A practical alternative for fluorescence in situ hybridisation to detect Her-2/ neu oncogene amplification in archival breast cancer samples. Am J Pathol 157: 1567-72, 2000.
28. Tanner M, Järvinen P and Isola J: Amplification of Her-2/neu and Topoisomerase IIa in primary and metastatic breast cancer. Cancer Res 61: 5345-48, 2001.
29. Tubbs RR, Pettay JD, Roche MH, Stoler RB, Jenkins RB and Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19: 2714-2719, 2001.
30. Xu R, Perle MA, Inghirami G et al: Amplification of Her-2/neu gene in Her-2 neu-overexpressing and nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15: 116-124, 2002.